Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

In this issue, Gainor and colleagues report on the immunogenicity of personalized neoantigen-encoding mRNA vaccines that elicit measurable polyfunctional CD8+ and CD4+ T-cell responses in patients whose tumors have been resected. Reactivity is substantiated to 20% to 30% of the predicted MHC-I and MHC-II epitopes in four patients with NSCLC postsurgically treated with the vaccine alone and in 12 patients with melanoma treated with their individualized vaccines plus pembrolizumab in the context of a phase 1 clinical trial (NCT03313778). See related article by Gainor et al., p. 2209.

Original publication

DOI

10.1158/2159-8290.cd-24-1196

Type

Journal article

Journal

Cancer discovery

Publication Date

11/2024

Volume

14

Pages

2021 - 2024

Addresses

Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.

Keywords

Humans, Neoplasms, RNA, Messenger, Cancer Vaccines, Adjuvants, Immunologic, Antigens, Neoplasm, Precision Medicine, Immunogenicity, Vaccine, mRNA Vaccines